How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/moraxella-catarrhalis-acute-otitis-media.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Moraxella Catarrhalis Acute Otitis Media — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Moraxella Catarrhalis Acute Otitis Media (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Moraxella Catarrhalis Acute Otitis Media, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cedax	ceftibuten	Burke Therap	Cephalosporin Antibacterial		1995-01-01
Zithromax	azithromycin	Pfizer Inc.	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Biaxin	clarithromycin	Generic (originally Abbott/AbbVie)	Macrolide Antimicrobial [EPC]	Potassium voltage-gated channel subfamily H member 2	1991-10-31
Cefzil	cefprozil	Teva Pharmaceuticals USA	Cephalosporin Antibacterial [EPC]		1991-01-01
Ceftin	CEFUROXIME AXETIL	GSK	Cephalosporin Antibacterial		1987-01-01
Augmentin 250	CLAVULANIC ACID	Dr Reddys Labs Inc	beta Lactamase Inhibitor		1984-01-01
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Amoxil	amoxicillin	Generic (originally Beecham/GSK)	Aminopenicillin (Beta-lactam antibiotic)	5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C	1972-01-01
Keflex	cefalexin	Shionogi	Cephalosporin Antibacterial	Solute carrier family 15 member 2	1971-01-01
Amoxicilli	Amoxicilli	Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.		5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

GSK · 2 drugs in Moraxella Catarrhalis Acute Otitis Media
· 2 drugs in Moraxella Catarrhalis Acute Otitis Media
Dr Reddys Labs Inc · 1 drug in Moraxella Catarrhalis Acute Otitis Media
Generic (originally Abbott/AbbVie) · 1 drug in Moraxella Catarrhalis Acute Otitis Media
Generic (originally Beecham/GSK) · 1 drug in Moraxella Catarrhalis Acute Otitis Media
King George's Medical University · 1 drug in Moraxella Catarrhalis Acute Otitis Media
Pfizer Inc. · 1 drug in Moraxella Catarrhalis Acute Otitis Media
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. · 1 drug in Moraxella Catarrhalis Acute Otitis Media
Shionogi · 1 drug in Moraxella Catarrhalis Acute Otitis Media
Teva Pharmaceuticals USA · 1 drug in Moraxella Catarrhalis Acute Otitis Media
Burke Therap · 1 drug in Moraxella Catarrhalis Acute Otitis Media

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Moraxella Catarrhalis Acute Otitis Media:

Cite this brief

Drug Landscape (2026). Moraxella Catarrhalis Acute Otitis Media — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/moraxella-catarrhalis-acute-otitis-media. Accessed 2026-06-10.

Moraxella Catarrhalis Acute Otitis Media full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing